Competition between IL-1, IL-1ra and TGF-β1 modulates the response of the ELA4.NOB-1/CTLL bioassay: Implications for clinical investigations

Inflammation Research

Volumn 53, Issue 2, 2004, Pages 60-65

  Ashwood, P ^a   Harvey, R ^a   Verjee, T ^a   Wolstencroft, R ^a   Thompson, R P H ^a   Powell, J J ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Bioassay; ELISA; Interleukin 1; Interleukin 1 receptor antagonist; Transforming growth factor 1

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NEUTRALIZING ANTIBODY; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; BIOASSAY; CELL LINE; COCULTURE; CONTROLLED STUDY; DOSE RESPONSE; MOUSE; NONHUMAN; T LYMPHOCYTE;

ANIMALS; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; CELL DIVISION; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; LYMPHOMA; MICE; RECOMBINANT PROTEINS; SIALOGLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; THYMIDINE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 1242306734     PISSN: 10233830     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00011-003-1220-6     Document Type: Article

References (33)

1. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin 1. Immunol Today 1986; 7: 45-56.
2. Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-52.
3. Mahida YR, Wu K, Jewell DP. Enhanced production of IL-1β by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease. Gut 1989; 30: 835-8.
4. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease-enhanced production during active disease. Gut 1990; 31: 686-9.
5. Isaacs KI, Balfour Sartor R, Hoskill S. Cytokine mRNA profiles in IBD mucosa detected by polymerase chain reaction amplification. Gastroenterology 1992; 103: 1587-95.
6. Stevens C, Walz G, Singaram C, Lipman ML, Zanker B, Muggia A et al. Tumor necrosis factor-α, interleukin-1β, and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-26.
7. Gröttrup-Wolfers E, Moeller J, Karbach U, Müller-Lissner S, Endres S. Elevated cell-associated levels of interleukin 1β and interleukin 6 in inflamed mucosa of inflammatory bowel disease. Eur J Clin Invest 1996; 26: 115-22.
8. Casini-Raggi V, Kam L, Chong YJT, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1ra in inflammatory bowel disease. J Immunol 1995; 154: 2434-40.
9. Andus T, Daig R, Vogl D, Aschenbrenner E, Lock G, Hollerbach K et al. Imbalance of the interleukin 1 system in colonic mucosa-association with intestinal inflammation and interleukin 1 receptor agonist genotype 2. Gut 1997; 41: 651-7.
10. Dionne S, D'Agata ID, Hiscott J, Vanounou T, Seidman EG. Colonic explant production of IL-1 and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp Immunol 1998; 112: 435-42.
11. Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk WW, Gross V et al. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 2000; 46: 350-8.
12. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110: 975-84.
13. DiMola FF, Friess H, Scheuren A, Di Sebastiano P, Graber H, Egger B et al. Transforming growth factor-βs and their signaling receptors are coexpressed in Crohn's disease. Ann Surg 1999; 229: 67-75.
14. Xian CJ, Xu X, Mardell CE, Howarth GS, Byard RW, Moore DJ et al. Site-Specific Changes in Transforming Growth Factor-α and -β1 Expression in Colonic Mucosa of Adolescents with Inflammatory Bowel Disease. Scand J Gastroenterol 1999; 6: 591-600.
15. Borruel N, Casellas F, Mourelle M, Armengol J-R. In human chronic ulcerative colitis (CUC) mucosal transforming growth factor 1β (TGF-1β) may intervene in the remission/relapse balance. Gastroenterology 1996; 110: A869.
16. 3 U/ml of interleukin-2. J Immunol Methods 1987; 99: 7-11.
17. Ghiara P, Scapigliati G, Tagliabue A, Boraschi D. Characterization of receptors for IL-1 alfa and Il-1 beta on lymphoid and non lymphoid cells. Immunol Res 1989; 1: 13-7.
18. Bird TA, Gearing AJH, Saklatvala J. Murine interleukin-1 receptor: Differences in binding properties between fibroblastic and thymoma cells and evidence for a two-chain receptor model. FEBS Lett 1987; 225: 21-3.
19. Randall LA. A novel sensitive bioassay for TGF-β1. J Immunol 1993; 164: 61-3.
20. Wadhwa M, Dilger P, Tubbs J, Mire-Sluis A, Barrowcliffe T, Thorpe R. Identification of transforming growth factor-β as a contaminant in factor VIII concentrates: A possible link with immunosuppressive effects in Hemophiliacs. Blood 1994; 84: 2021-5.
21. Von Hoegen I, Falk W, Kojouharoff G, Krammer PH. Internalization of interleukin 1 (IL-1)-induced IL 2 receptor expression and IL 2 secretion of EL4 thymoma cells. Eur J Immunol 1989; 19: 329-33.
22. Zumbihl R, Dornand J, Fischer T, Cabane S, Rappuoli R, Bouaboula M et al. IL-1 stimulates a diverging signaling pathway in EL4 6.1 thymoma cells. J Immunol 1995; 155: 181-9.
23. Fisher CJ, Dhainait JF, Opal SM, Pribble JP, Balk RA, Slotman GJ et al. Recombinant human IL-1ra in the treatment of patients with sepsis syndrome. JAMA 1994; 271: 1836-43.
24. Arend WP, Weglus HG, Thompson RC, Elsenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990; 85: 1694-7.
25. Dripps DJ, Brandhuber BJ, Thompson RC, Eisenberg SP. Interleukin-1 (IL-1), receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction. J Biol Chem 1991; 266: 10331-6.
26. Turner M, Chantry D, Katsikis P, Berger A, Brennan FM, Feldmann. Induction of the interleukin 1 receptor antagonist protein by transforming growth factor-β*. Eur J Immunol 1991; 21: 1635-9.
27. Ohta M, Greenberger JS, Anklesaria P, Bassols A, Massague J. Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells. Nature 1987; 329: 539-42.
28. Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant Tumour Necrosis Factor α. J Exp Med 1987; 166: 991-4.
29. Dubois CM, Ruscetti FW, Palaszynski EW, Falk LA, Oppenheim JJ, Keller JR. Transforming growth factor β is a potent inhibitor of interleukin 1 (IL-1) receptor expression: Proposed mechanism of inhibition of IL-1 action. J Exp Med 1990; 172: 737-44.
30. Siese A, Jaros PP, Willig A. Analysis of interleukin (IL)-1β and transforming growth factor (TGF)-β-induced signal transduction pathways in IL-2 and TGF-β secretion and proliferation in the thymoma cell line ELA4.NOB-1. Scand J Immunol 1999; 49: 139-48.
31. Cominelli F, Pizarro TT. Interleukin 1 and IL-1ra in IBD. Aliment Pharmacol Ther 1996; 10: 49-53.
32. Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998; 22: 382.
33. Fell JME, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14: 281-9.